CETP inhibition, statins and diabetes

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Statins reduce ASCVD events but can increase new-onset diabetes risk in predisposed individuals.
• Cholesteryl ester transfer protein (CETP) inhibitors offer an alternative mechanism for cardiovascular risk reduction.

Purpose of the Study:

• To evaluate the efficacy of anacetrapib, a CETP inhibitor, in reducing ASCVD events.
• To assess the impact of anacetrapib on the incidence of new-onset diabetes.
• To explore the potential benefits of combining statins with CETP inhibitors for high-risk populations.

Main Methods:

• The study involved assessing cardiovascular outcomes in patients treated with anacetrapib.
• Incidence of new-onset diabetes was monitored as a key secondary endpoint.
• Comparative analysis of anacetrapib's effects versus statin therapy was performed.

Main Results:

• Anacetrapib significantly reduced the risk of coronary events beyond the benefits of statin therapy.
• Anacetrapib demonstrated a decrease in the risk of developing new-onset diabetes.
• Statins, while effective for ASCVD, were associated with an increased risk of new-onset diabetes.

Conclusions:

• Anacetrapib provides additional ASCVD risk reduction and lowers the risk of new-onset diabetes.
• Combination therapy with statins and CETP inhibitors may be a viable strategy for high-ASCVD-risk individuals with diabetes risk factors.
• Further trials are warranted to confirm the diabetes-protective effects of CETP inhibitors.